Yin Min, Zhang Yan, Yu Haibo, Li Xia
Key Laboratory of Diabetes Immunology, Ministry of Education, Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital of Central South University, Changsha, China.
Front Cell Dev Biol. 2021 Apr 15;9:665412. doi: 10.3389/fcell.2021.665412. eCollection 2021.
The regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs) have laid a sound foundation for their clinical application in various diseases. However, the clinical efficiency of MSC treatments varies depending on certain cell characteristics. Among these, the roles of cell aging or senescence cannot be excluded. Despite their stemness, evidence of senescence in MSCs has recently gained attention. Many factors may contribute to the senescence of MSCs, including MSC origin (biological niche), donor conditions (age, obesity, diseases, or unknown factors), and culture conditions With the rapidly increasing prevalence of diabetes mellitus (DM) and gestational diabetes mellitus (GDM), the effects of hyperglycemia on the senescence of MSCs should be evaluated to improve the application of autologous MSCs. This review aims to present the available data on the senescence of MSCs, its relationship with hyperglycemia, and the strategies to suppress the senescence of MSCs in a hyperglycemic environment.
间充质干细胞（MSCs）的再生和免疫调节特性为其在各种疾病中的临床应用奠定了坚实基础。然而，MSCs治疗的临床效果因某些细胞特性而异。其中，细胞衰老的作用不可排除。尽管MSCs具有干性，但近年来MSCs衰老的证据已受到关注。许多因素可能导致MSCs衰老，包括MSCs来源（生物龛）、供体条件（年龄、肥胖、疾病或未知因素）以及培养条件。随着糖尿病（DM）和妊娠糖尿病（GDM）的患病率迅速上升，应评估高血糖对MSCs衰老的影响，以改善自体MSCs的应用。本综述旨在介绍关于MSCs衰老的现有数据、其与高血糖的关系以及在高血糖环境中抑制MSCs衰老的策略。
